Uncategorized
Aerie initiates phase 2b study of glaucoma drug
Aerie Pharmaceuticals has initiated a phase 2b study of a novel drug for the treatment of glaucoma, according to a press release. PG324 is a fixed-combination of Aerie’s AR-13324 and latanoprost, the release said.